Library Item - Page 42 of 792 Posts on Medivizor
Navigation Menu

Library Item Posts on Medivizor

Comparing pessaries and disposable continence devices for managing stress incontinence

Comparing pessaries and disposable continence devices for managing stress incontinence

Posted by on Oct 25, 2021 in Urinary incontinence | 0 comments

In a nutshell This study compared two treatments for stress urinary incontinence (SUI), continence pessaries (CP) and disposable intravaginal continence devices (DICD). It found that both treatments reduced symptoms of stress incontinence after 4 weeks in 75-80% of patients. Some background SUI is a condition that commonly affects women...

Read More

Impact of 5-year baricitinib treatment for active, rheumatoid arthritis in preventing radiographic progression of joint damage.

Impact of 5-year baricitinib treatment for active, rheumatoid arthritis in preventing radiographic progression of joint damage.

Posted by on Oct 25, 2021 in Rheumatoid Arthritis | 0 comments

In a nutshell This study evaluated the effect of oral baricitinib (Olumiant) on the prevention of radiographic progression of joint damage over 5 years in patients with active rheumatoid arthritis (RA). The data showed that patients treated with oral baricitinib had less radiographic progression over 5 years, compared to those initially given a...

Read More

Do insulin analogues differ in effectiveness and safety for the treatment of diabetes?

Do insulin analogues differ in effectiveness and safety for the treatment of diabetes?

Posted by on Oct 25, 2021 in Diabetes mellitus | 0 comments

In a nutshell This study assessed the effectiveness and safety of different long-acting and short-acting insulins for the treatment of patients with diabetes. The data supported the use of long-acting insulins instead of neutral protamine Hagedorn (NPH) insulin (Humulin N; Novolin N), as basal insulin for patients with type 2 diabetes (T2D). Some...

Read More

Extended therapy with letrozole for 5 years improves survival outcomes in postmenopausal patients with hormone positive early-stage breast cancer.

Extended therapy with letrozole for 5 years improves survival outcomes in postmenopausal patients with hormone positive early-stage breast cancer.

Posted by on Oct 24, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of extended therapy with letrozole (LET; Femara) for 5 years versus the standard therapy of 2-3 years for the treatment of postmenopausal women with early-stage breast cancer (BC). The data showed that extended treatment with LET for 5 years significantly improved the survival outcomes...

Read More

Evaluating the effectiveness and safety of capecitabine maintenance versus active monitoring for the treatment of patients with metastatic colorectal cancer.

Evaluating the effectiveness and safety of capecitabine maintenance versus active monitoring for the treatment of patients with metastatic colorectal cancer.

Posted by on Oct 24, 2021 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of capecitabine (Xeloda) as maintenance therapy versus active monitoring for the treatment of patients with stable metastatic colorectal cancer (mCRC). The data showed that capecitabine maintenance improved survival without cancer worsening with manageable side effects for these...

Read More

Evaluating the long-term outcomes of stereotactic ablative radiation therapy and video-assisted thoracic surgery in patients with early-stage non-small cell lung cancer.

Evaluating the long-term outcomes of stereotactic ablative radiation therapy and video-assisted thoracic surgery in patients with early-stage non-small cell lung cancer.

Posted by on Oct 24, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated the long-term outcomes of stereotactic ablative radiation therapy (SABR) and video-assisted thoracic surgery (VATS) for the treatment of patients with early-stage non-small cell lung cancer (NSCLC). The data showed that both SABR and VATS led to similar long-term survival outcomes. Some background...

Read More

Evaluating the long-term functional and oncological outcomes after open versus robot-assisted prostate surgery for localized prostate cancer.

Evaluating the long-term functional and oncological outcomes after open versus robot-assisted prostate surgery for localized prostate cancer.

Posted by on Oct 24, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the long-term functional and oncological outcomes of robotic-assisted laparoscopic radical prostatectomy (RALP) and open retropubic radical prostatectomy (RRP) for the treatment of patients with localized prostate cancer (PCa). This study found that RALP was associated with better oncological outcomes compared to...

Read More

Evaluating the safety and effectiveness of trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer.

Evaluating the safety and effectiveness of trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer.

Posted by on Oct 24, 2021 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of trastuzumab deruxtecan (Enhertu) in patients with previously untreated metastatic HER2-mutant non-small-cell lung cancer (NSCLC). The data showed that trastuzumab deruxtecan was safe and showed strong anticancer activity in these patients. Some background NSCLC is the most common form...

Read More

Does tebentafusp provide survival benefit in patients with advanced uveal melanoma?

Does tebentafusp provide survival benefit in patients with advanced uveal melanoma?

Posted by on Oct 17, 2021 in Melanoma | 0 comments

In a nutshell The study aimed to investigate the safety and effectiveness of immunotherapy drug tebentafusp in previously untreated advanced uveal melanoma. The study showed that tebentafusp is effective and improved the overall survival in patients with uveal melanoma. Some background Melanoma is an aggressive kind of skin cancer. Uveal melanoma...

Read More